Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay H Traverse

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Circulation|July 16, 2003
Clinical, angiographic, and interventional follow-up of patients with aortic-saphenous vein graft connectorsJay H Traverse, Michael R Mooney, Wesley R Pedersen, et al.
International Journal of Cardiology|October 22, 2020
Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohortAmish N Raval, Peter V Johnston, Henricus J Duckers, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 6, 2016
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunctionTimothy D Henry, Carl J Pepine, Charles R Lambert, et al.
Circulation|March 24, 2010
Oxidative stress regulates left ventricular PDE5 expression in the failing heartZhongbing Lu, Xin Xu, Xinli Hu, et al.
American Heart Journal|July 5, 2021
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerationsThomas J Povsic, Timothy D Henry, E Magnus Ohman, et al.
Plos One|August 26, 2020
Impaired therapeutic efficacy of bone marrow cells from post-myocardial infarction patients in the TIME and LateTIME clinical trialsXiaoyin Wang, Lourdes I Chacon, Ronak Derakhshandeh, et al.
Circulation Research|July 8, 2015
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart FailureEmerson C Perin, Kenneth M Borow, Guilherme V Silva, et al.
Cell Transplantation|August 21, 2016
ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and DesignTarun Chakravarty, Raj R Makkar, Deborah D Ascheim, et al.
The Journal of Invasive Cardiology|June 17, 2022
Incidence, Treatment, and Outcomes of Coronary Artery Perforation During Percutaneous Coronary InterventionVennela Avula, Judit Karacsonyi, Spyridon Kostantinis, et al.
Circulation Research|January 4, 2019
NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial InfarctionJay H Traverse, Cory M Swingen, Timothy D Henry, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Circulation|July 16, 2003
Clinical, angiographic, and interventional follow-up of patients with aortic-saphenous vein graft connectorsJay H Traverse, Michael R Mooney, Wesley R Pedersen, et al.
International Journal of Cardiology|October 22, 2020
Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohortAmish N Raval, Peter V Johnston, Henricus J Duckers, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|May 6, 2016
The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunctionTimothy D Henry, Carl J Pepine, Charles R Lambert, et al.
Circulation|March 24, 2010
Oxidative stress regulates left ventricular PDE5 expression in the failing heartZhongbing Lu, Xin Xu, Xinli Hu, et al.
American Heart Journal|July 5, 2021
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerationsThomas J Povsic, Timothy D Henry, E Magnus Ohman, et al.
Plos One|August 26, 2020
Impaired therapeutic efficacy of bone marrow cells from post-myocardial infarction patients in the TIME and LateTIME clinical trialsXiaoyin Wang, Lourdes I Chacon, Ronak Derakhshandeh, et al.
Circulation Research|July 8, 2015
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart FailureEmerson C Perin, Kenneth M Borow, Guilherme V Silva, et al.
Cell Transplantation|August 21, 2016
ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and DesignTarun Chakravarty, Raj R Makkar, Deborah D Ascheim, et al.
The Journal of Invasive Cardiology|June 17, 2022
Incidence, Treatment, and Outcomes of Coronary Artery Perforation During Percutaneous Coronary InterventionVennela Avula, Judit Karacsonyi, Spyridon Kostantinis, et al.
Circulation Research|January 4, 2019
NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial InfarctionJay H Traverse, Cory M Swingen, Timothy D Henry, et al.
Pageof 10